Trial Profile
Comparing the survival outcomes between the hypomethylating agents (HMAs) in SEER- Medicare database.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2017
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 29 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.